Dr. Chengcang Charles Wu, founder/CEO of Intact Genomics, Inc. has over 20 years of research and development experience in 100kb large DNA technology for genomic studies, metagenomics, large-scale natural production and drug discovery, development, including five years as Vice President of Lucigen Corporation. He is one of leading inventors of plant artificial chromosomes at Pioneer/DuPont. Dr. Wu has published a pending patent on fungal artificial chromosome (FAC) technology and several other provisional patent applications at Intact Genomics (www.intactgenomics.com).
I am building a team of IG Therapeutics, a whole-owned division of Intact Genomics, Inc. We focus on early-stage drug discovery and development by addressing the unmet medical need for novel drugs that can effectively treat infectious diseases. We utilize a transformative metagenomic strategy to unearth medicines from nature that are devoid of the historical major bottleneck of more than 99% re-discovery rate of large-scale natural product discovery by existing culture-based methods. IG Therapeutics’ platform overcomes the problems of more than 99.9% unculturable microbes and at least 90% silent large gene clusters. We have both patents and trade secrets for our novel technologies. We intend to raise investment (about $20M) to advance thousands of new small molecules through pre-clinical development, whereby we can bring our technologies to a key value inflection point where we can then partner with large biotech and pharmaceutical companies at the value of at least $500M within 3 to 5 years.